The potential role of macrophage migration inhibitory factor on the migration of vascular smooth muscle cells

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 1, 2008, Pages 13-19

  Okamoto, Toshiya ^a   Atsumi, Toshiya ^a   Shimizu, Chikara ^a   Yoshioka, Narihito ^a   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; MIF; Migration; Vascular smooth muscle cells

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

ANIMAL; ARTICLE; AUTOCRINE EFFECT; CELL MOTION; HUMAN; METABOLISM; MOUSE; PARACRINE SIGNALING; PHYSIOLOGY; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; AUTOCRINE COMMUNICATION; CELL MOVEMENT; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MUSCLE, SMOOTH, VASCULAR; PARACRINE COMMUNICATION; RATS;

EID: 45149113427     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E495     Document Type: Article

References (32)

1. Bernhagen J, Calandra T, and Bucala R: Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J Mol Med, 1998; 76:151-161
2. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, and Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature, 1993; 365:756-759
3. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, and Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature, 1995; 377:68-71
4. Bernhagen J, Bacher M, Calandra T, Metz CN, Doty SB, Donnelly T, and Bucala R: An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med, 1996; 183:277-282
5. Calandra T and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol, 2003; 3:791-800
6. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, Lau CP, and Lan HY: De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res, 2000; 87:1202-1208
7. Nishihira. J, Koyama Y, and Mizue Y: Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine, 1998; 10:199-205
8. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993; 362:801-809
9. Joris I, Zand T, Nunnari JJ, Krolikowski FJ, and Majno G: Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol, 1983; 113:341-358
10. Atsumi T, Nishihira J, Makita Z, and Koike T: Enhancement of oxidised low-density lipoprotein uptake by macrophages in response to macrophage migration inhibitory factor. Cytokine, 2000; 12:1553-1556
11. Ferns GA and Avades TY: The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol, 2000; 81:63-88
12. Libby P: Inflammation in atherosclerosis. Nature, 2002; 420:868-874
13. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 1998; 394:894-897
14. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, Kleemann R, Bernhagen J, and Ihling C: Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation, 2002; 105:1561-1566
15. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, and Weber C: Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-defident mice. Circulation, 2004; 109:380-385
16. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, Metz CN, Bucala R, Fang K, Simon DI, Chapman HA, Libby P, and Shi GP: Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation, 2004; 109:3149-3153
17. Steinbrecher UP: Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem, 1987; 262:3603-3608
18. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT and Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock, 2004; 22:309-313
19. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, and Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med, 2000; 6:164-170
20. Calandra T, Bernhagen J, Mitchell RA, and Bucala R: The macrophage is an important and previously unrecognized source of macropbage migration inhibitory factor. J Exp Med, 1994; 179:1895-1902
21. Chen Z, Sakuma M, Zago AC, Zhang Y, Shi C, Leng L, Mizue Y, Bucala R, and Simon D: Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol, 2004; 24:709-714
22. Burger-Kentischer A, Gobel H, Kleemann R, Zernecke A, Bucala R, Leng L, Finkelmeier D, Geiger G, Schaefer HE, Schober A, Weber C, Brunner H, Rutten H, Ihling C, and Bernhagen J: Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis, 2006; 184:28-38
23. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, and Bernhagen J: Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature, 2000; 408:211-216
24. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, and Bucala R: MIF signal transduction initiated by binding to CD74. J Exp Med, 2003; 197:1467-1476
25. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, and Bernhagen J: Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal, 2006; 18:688-703
26. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, and Vera PL: Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol, 2006; 177:8730-8739
27. Shi X, Leng L, Wang T, Wang W, Du Y, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, and Bucala R: CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity, 2006; 25:595-606
28. Amin MA, Volperf OV, Woods JM, Kumar P, Harlow LA, and Koch AE: Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res, 2003; 93:321-329
29. Sun B, Nishihira. J, Yoshiki T, Kondo M. Sato Y, Sasaki F, and Todo S: Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res, 2005; 11:1050-1058
30. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, and Chaudhuri A: Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab, 2004; 89:5043-5047
31. Herder C, Kolb H, Koenig W, Haastert R, Muller-Scholze S, Rathmann W, Holle R, Thorand B, and Wichmann HE: Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care, 2006; 29:368-371
32. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ, and Tracey KJ: ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem, 2005; 280:36541-36544